# Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females

> **NCT04422366** · PHASE3 · RECRUITING · sponsor: **Shanghai Bovax Biotechnology Co., Ltd.** · enrollment: 8000 (estimated)

## Conditions studied

- Cervical Cancer
- Vulvar Cancer
- Vaginal Cancer
- CIN1
- CIN2
- CIN3
- VaIN1
- VaIN2
- VaIN3
- Genital Wart
- VIN 1
- VIN 2
- VIN 3
- AIS

## Interventions

- **BIOLOGICAL:** 9-valent Human Papillomavirus (Types 6, 11, 16, 18,31,33,45,52 and 58) Recombinant Vaccine (Hansenula Polymorpha)
- **BIOLOGICAL:** GARDASIL®

## Key facts

- **NCT ID:** NCT04422366
- **Lead sponsor:** Shanghai Bovax Biotechnology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-04-28
- **Primary completion:** 2027-09-15
- **Final completion:** 2029-09-15
- **Target enrollment:** 8000 (ESTIMATED)
- **Last updated:** 2024-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04422366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04422366, "Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04422366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*